BioAge Labs (BIOA) analyst forecast and price target
Analyst forecast
Consensus of 10 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| UBS | Initiated Coverage | Neutral | $8.00 | Oct 12, 2026 |
| Roth Capital | Maintained | Buy | $25.00 | Sep 9, 2026 |
| BTIG | Maintained | Buy | $40.00 | Sep 8, 2026 |
| BTIG | Maintained | Buy | $40.00 | Aug 6, 2026 |
| BTIG | Maintained | Buy | $40.00 | Aug 3, 2026 |
| Needham | Maintained | Buy | $35.00 from $50.00 | Jul 31, 2026 |
| Roth Capital | Initiated Coverage | Buy | $36.00 | May 27, 2026 |
| BTIG | Initiated Coverage | Buy | $40.00 | May 13, 2026 |
| Needham | Initiated Coverage | Buy | $50.00 | Mar 27, 2026 |
| Citigroup | Maintained | Buy | $52.00 from $15.00 | Mar 10, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $60.00 | Feb 25, 2026 |
| Jefferies | Upgraded | Hold → Buy | $62.00 from $9.00 | Feb 18, 2026 |
| Piper Sandler | Initiated Coverage | Overweight | $73.00 | Jan 27, 2026 |
| Morgan Stanley | Upgraded | Underweight → Equal-Weight | $12.00 from $5.00 | Dec 8, 2025 |
| Citigroup | Maintained | Buy | $15.00 from $10.00 | Oct 29, 2025 |
| Citigroup | Upgraded | Neutral → Buy | $10.00 from $5.00 | Oct 22, 2025 |
| Citigroup | Maintained | Neutral | $5.00 from $7.00 | Mar 24, 2025 |
| Morgan Stanley | Initiated Coverage | Underweight | $5.00 | Mar 7, 2025 |
| William Blair | Initiated Coverage | Market Perform | — | Feb 28, 2025 |
| Jefferies | Downgraded | Buy → Hold | $7.00 from $42.00 | Dec 9, 2024 |
Frequently asked questions
What is the price target for BIOA stock?
The average 12-month analyst price target for BioAge Labs (BIOA) is $27.00, with a high estimate of $40.00 and a low of $8.00, across 4 analysts.
Is BIOA a buy, sell, or hold?
Analysts covering BioAge Labs currently average a Buy rating: 7 buy, 3 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for BIOA?
The average price target of $27.00 implies 398.15% upside from the last price of $5.42.
What is the latest analyst rating on BIOA?
On Oct 12, 2026, UBS initiated coverage of BioAge Labs at Neutral with a price target of $8.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.